Grapiprant is under clinical development by Ikena Oncology and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Grapiprant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Grapiprant overview

Grapiprant (RQ-0000007, RQ-7, MR10A7) is under development for the treatment of hepatocellular carcinoma, triple negative/inflammatory breast cancer, non small cell lung cancer, cancer pain, osteoarthritis pain,metastatic colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, chronic pain, osteoarthritis pain, post-operative pain, tumors including liver cancer, colorectal cancer, breast cancer, non-small cell lung cancer adenocarcinoma and gastroenterological cancer, autoimmune disorders and allergies. It is administered intravenously and orally. RQ-0000007 (MR10A7) acts by targeting EP4 receptor.

It was also under development for the treatment of non-small cell lung cancer.

Ikena Oncology overview

Ikena Oncology, formerly Kyn Therapeutics is a health care provider. The company is advancing novel immunometabolic therapies for the treatment of cancers. Its pipeline development programs include EP4 antagonist IK-007, which promotes immune suppression across a diverse range of immune cells; AHR antagonist, prevent AHR-modulated tumor promotion; and IK-412, a kynurenine-degrading enzyme (Kynase) that targets implicated in immunosuppression across a range of tumor types through multiple immune cell effects. Its immunosuppressive pathway inhibits the IDO and TDO pathway, enabling the body’s immune system to attack the tumor. Ikena Oncology is headquartered in Boston, Massachusetts, the US.

For a complete picture of Grapiprant’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.